A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multi-Center Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)
Phase of Trial: Phase II/III
Latest Information Update: 12 Dec 2015
At a glance
- Drugs N-1-methylnicotinamide (Primary)
- Indications Hyperlipoproteinaemia type V; Hypertriglyceridaemia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 13 Jan 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 13 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.